中國公共採購(01094.HK)擬折讓約19.78%配發4800萬股 籌資1758萬港元
格隆匯9月8日丨中國公共採購(01094.HK)發佈公吿,於2021年9月8日,公司與認購人東峯環球有限公司訂立認購協議,據此,認購人已同意認購,而公司已同意配發及發行認購股份(即4800萬股新股份),相當於公司現有已發行股本約19.98%;及經配發擴大後已發行股本約16.65%。認購價每股認購股份0.361港元,較9月8日收市價(即0.45港元)折讓約19.78%。
董事認為認購事項將改善集團的營運資金狀況。估計發行認購股份所得款項淨額將約為1758萬港元。公司擬將所得款項淨額用以增強其一般營運資金,以支持集團現有業務的日常運營。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.